QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
NASDAQ:TVTX

Travere Therapeutics Stock Forecast, Price & News

$28.55
+0.08 (+0.28%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.89
$29.30
50-Day Range
$23.55
$30.89
52-Week Range
$12.75
$33.09
Volume
1.24 million shs
Average Volume
822,671 shs
Market Capitalization
$1.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.73
30 days | 90 days | 365 days | Advanced Chart
Receive TVTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Travere Therapeutics logo

About Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Headlines

Travere Therapeutics, Inc. (TVTX)
October 29, 2021 |  realmoney.thestreet.com
Do Hedge Funds Love Travere Therapeutics, Inc. (TVTX)?
October 25, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TVTX
Employees
262
Year Founded
N/A

Sales & Book Value

Annual Sales
$198.32 million
Book Value
$5.02 per share

Profitability

Net Income
$-169.43 million
Net Margins
-113.07%
Pretax Margin
-113.10%

Debt

Price-To-Earnings

Miscellaneous

Free Float
58,587,000
Market Cap
$1.75 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/28/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

1024th out of 1,390 stocks

Pharmaceutical Preparations Industry

488th out of 669 stocks

Analyst Opinion: 2.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Travere Therapeutics (NASDAQ:TVTX) Frequently Asked Questions

Is Travere Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Travere Therapeutics stock.
View analyst ratings for Travere Therapeutics
or view top-rated stocks.

When is Travere Therapeutics' next earnings date?

Travere Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Travere Therapeutics
.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) released its earnings results on Thursday, October, 28th. The company reported ($0.59) EPS for the quarter, beating the Zacks' consensus estimate of ($0.72) by $0.13. The business earned $68.20 million during the quarter, compared to analysts' expectations of $60.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 82.45% and a negative net margin of 113.07%. The company's revenue was up 33.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.44) EPS.
View Travere Therapeutics' earnings history
.

What price target have analysts set for TVTX?

6 equities research analysts have issued 1-year price objectives for Travere Therapeutics' stock. Their forecasts range from $19.00 to $42.00. On average, they expect Travere Therapeutics' stock price to reach $32.17 in the next year. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for Travere Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Travere Therapeutics' key executives?

Travere Therapeutics' management team includes the following people:

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (6.57%), VR Adviser LLC (2.83%), Renaissance Technologies LLC (2.03%), Geode Capital Management LLC (1.61%), Dimensional Fund Advisors LP (1.59%) and Laurion Capital Management LP (1.24%). Company insiders that own Travere Therapeutics stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Steve Aselage and William E Rote.
View institutional ownership trends for Travere Therapeutics
.

Which major investors are selling Travere Therapeutics stock?

TVTX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Renaissance Technologies LLC, Great Point Partners LLC, Dimensional Fund Advisors LP, Cubist Systematic Strategies LLC, Pura Vida Investments LLC, Squarepoint Ops LLC, and Jane Street Group LLC. Company insiders that have sold Travere Therapeutics company stock in the last year include Elizabeth E Reed, Eric M Dube, Laura Clague, Noah L Rosenberg, Peter Heerma, Steve Aselage, and William E Rote.
View insider buying and selling activity for Travere Therapeutics
or view top insider-selling stocks.

Which major investors are buying Travere Therapeutics stock?

TVTX stock was bought by a variety of institutional investors in the last quarter, including VR Adviser LLC, International Biotechnology Trust PLC, BioImpact Capital LLC, Thrivent Financial for Lutherans, Polar Asset Management Partners Inc., Laurion Capital Management LP, Connor Clark & Lunn Investment Management Ltd., and Millennium Management LLC.
View insider buying and selling activity for Travere Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Travere Therapeutics?

Shares of TVTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Travere Therapeutics' stock price today?

One share of TVTX stock can currently be purchased for approximately $28.55.

How much money does Travere Therapeutics make?

Travere Therapeutics has a market capitalization of $1.75 billion and generates $198.32 million in revenue each year. The company earns $-169.43 million in net income (profit) each year or ($4.56) on an earnings per share basis.

How many employees does Travere Therapeutics have?

Travere Therapeutics employs 262 workers across the globe.

What is Travere Therapeutics' official website?

The official website for Travere Therapeutics is www.retrophin.com.

Where are Travere Therapeutics' headquarters?

Travere Therapeutics is headquartered at 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at (888) 969-7879, via email at [email protected], or via fax at 302-645-1280.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.